1. In Vivo
  2. >>Market Intelligence

Going Early For Maximum Long Term Value From Medtech Deals

For Medtech Deal-Makers The Best Opportunities Must Be Developed Well In Advance Of M&A

 
• By Ashley Yeo

Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.

business card

“I would never have thought 2021 would turn out as it did,” said John Babitt, a Minneapolis-based partner with EY. He was referring to the uncharted heights achieved last year in medtech M&A deal-making and venture capital funding.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

Biotech Leaders Ponder Trump’s Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Reforming The Rx Rulers: A New Script For PBMs

 
• By Andrew Cox

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

 
• By David Wild

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.

BioBytes: AI-Related Deals In Q1 2025

 
• By David Wild

AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.

More from In Vivo

Deals Shaping The Industry, March 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

Merck’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.